Mukka Proteins Q2 FY27 Investor Presentation
Mukka Proteins Ltd · Investor Presentation · 10 Nov 2026, 4:13 pm
Mukka Proteins Q2 FY27 Investor Presentation Mukka Proteins reported consolidated Q2 FY27 revenue of ₹508.9 crore, up 108.1% YoY, with EBITDA rising 90.5% YoY to ₹50.1 crore (9.9% margin) and PAT surging 156.5% YoY to ₹17.7 crore. For H1 FY27, revenue reached ₹998.5 crore with PAT of ₹36.3 crore. Exports contributed 81.3% of Q2 FY27 revenue. Operational milestones include commercial production at the 21,249 sq. mt Al Joubah facility in Oman with US FDA registration, and securing a ₹474.89 crore leachate treatment contract from BSWML. Management targets over ₹3,000 crore revenue by FY30.
Original exchange filing (PDF)
More announcements from Mukka Proteins Ltd
- Intimation of Press Release. · 08 Nov 2026
- Intimation of revision of terms of investment in Swachha Eco Solutions Private Limited. · 07 Nov 2026
- Financial Results for the quarter and half year ended 30th September 2026. · 07 Nov 2026
- Mukka Proteins Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 07 Nov 2026
- Intimation of Statement of Deviation and Variation for the quarter ended 30th September 2026. · 07 Nov 2026
- Intimation of Outcome of Board Meeting · 07 Nov 2026
- MUKKA PROTEINS LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 07 Nov 2026
- Mukka Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve the unaudited financial results .... · 07 Nov 2026
